CSF1R and cancer: Similarly, a triple combination of anti-PD1, an anti-CSF1R antibody, and a PDAC vaccine (GVAX) converted exhausted PD1+ T-cells to CD137+ activated effector T-cells, suggesting that adding a myeloid-targeting agent to vaccine-based cancer immunotherapy can reverse the anergy of T-cells in immune-quiescent tumors [148].